| zoledronic acid / Generic mfg. |
ACTRN12613000512729: A study to evaluate safety and feasibility of zoledronic acid to prevent joint complication (osteonecrosis) following chemotherapy for acute lymphoblastic leukemia or lymphoma in children and adolescents. |
|
|
| Recruiting | 1 | 10 | | | Sydney Children's Hospital Network, Oncology Department
The Childrens Hospital at Westmead | Acute lymphoblastic leukemia, Lymphoblastic lymphoma, Osteonecrosis | | | | |
ACTRN12612000136808: Phase I study of RAD001 (Everolimus) in combination with Fluvastatin and Zoledronic acid in patients with solid tumours |
|
|
| Active, not recruiting | 1 | 25 | | | St George Hospital, Novartis Pharmaceuticals Australia Pty Ltd | Advanced cancers | | | | |
ChiCTR-PPR-15007009: Adjuvant therapy with zoledronic acid to prevent bone metastases in patients with lung cancer: a prospective, randomized, controlled trial |
|
|
| Not yet recruiting | 1 | 120 | | zoledronic acid ;none | Chinese Navy General Hospital; Chinese Navy General Hospital, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD | lung cancer | | | | |
ACTRN12621001521819: Development of an Oral Preparation of Zoledronic Acid for Use in Postmenopausal Osteoporosis/Osteopenia |
|
|
| Completed | 1 | 30 | | | The University of Auckland, The University of Auckland | Osteoporosis, Osteopenia | | | | |
ChiCTR2000038593: The efficacy and adverse reactions of different infusion plan of zoledronic acid in patients with osteoporosis |
|
|
| Not yet recruiting | 1 | 96 | | infuse zoledronic acid 100% in one time ; infuse 20% of zoledronic acid for the first time,infuse the other 80% for the second time ;infuse 50% of zoledronic acid for the first time,infuse the other 50% for the second time ;infuse 80% of zoledronic acid for the first time,infuse the other 20% for the second time | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Self-financing | osteoporosis | | | | |
NCT03862833: Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant |
|
|
| Completed | 1 | 30 | Europe | IL2, Zoledronic Acid | Nantes University Hospital | Hematopoietic Stem Cell Transplantation | 08/23 | 08/23 | | |
NCT02508038: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors |
|
|
| Recruiting | 1 | 22 | US | TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate, Zoledronic Acid, Zometa | University of Wisconsin, Madison | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma | 12/24 | 12/25 | | |
NCT03173976: Anti-Osteoclast Therapy As Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial |
|
|
| Active, not recruiting | 1 | 17 | US | Zoledronic Acid, Zometa® | Mohammed Milhem, Rising Tide Foundation | Chondrosarcoma | 04/23 | 05/28 | | |
ChiCTR2200062684: A multicenter controlled study of vitamin K2 in combination with denosumab or zoledronic acid for the prevention and treatment of bone-related events in multiple myeloma |
|
|
| Not yet recruiting | 1 | 120 | | denosumab/zoledronic acid and vitamin K2 ;denosumab/zoledronic acid | Chengdu Third People's Hospital; Chengdu Third People's Hospital, Personal research funding | Multiple myeloma bone disease | | | | |
| Not yet recruiting | 1 | 16 | RoW | ETC-159, Pembrolizumab, Denosumab / Zoledronic Acid | National University Hospital, Singapore, EDDC (Experimental Drug Development Centre), A*STAR Research Entities | With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer | 12/26 | 06/27 | | |
ChiCTR-IPR-15006922: The effect of bisphosphonates and bone density on aseptic joint loosening of the hip |
|
|
| Recruiting | 1 | 190 | | alendronate ;zoledronate | Sun yet-sen memorial hospital, Sun yet-sen university; Sun yet-sen memorial hospital，Sun yet-sen university, Sun yet-sen memorial hospital, Sun yet-sen university | aseptic joint loosening of the hip | | | | |
ZAPOA, NCT05204836: Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury |
|
|
| Recruiting | 1 | 56 | Canada | Zoledronic Acid Injection, Taro-Zoledronic Acid, Dr. Reddy's Zoledronic Acid Injection, Placebo, Saline | University of Calgary | Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Rupture, Anterior Cruciate Ligament Injuries, Osteo Arthritis Knee | 12/24 | 12/24 | | |
Aflac-NBL-2002, NCT05400603: Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma |
|
|
| Recruiting | 1 | 24 | US | Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate | Emory University | Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma, Relapsed Osteosarcoma, Refractory Osteosarcoma | 12/25 | 12/25 | | |
NCT05053750: TAME: a Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (zoledronic Acid) in Women with Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
|
|
| Active, not recruiting | 1 | 14 | US | Paclitaxel/Bev (control), Taxol, Paclitaxel/Bev + ZA (experimental) | M.D. Anderson Cancer Center, Gateway for Cancer Research, National Cancer Institute (NCI) | Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer | 02/27 | 02/27 | | |
